Type here...

Home
About
Editor’s Corner
Contribute
Contact Us

Thought Leadership
Healthcare C-Suite Movements
Digital in Pharma
Events
Solutions & Pricing
Partner

Instagram

Twitter

Monday, June 22, 2026

22.7 C

Bengaluru

Home
About
Editor’s Corner
Contribute
Contact Us

My account

Get into your account.

type here...

Facebook

Twitter

Youtube

Thought Leadership
Healthcare C-Suite Movements
Digital in Pharma
Events
- FFE+CEO RT
- BrandStorm
Solutions & Pricing
Partner

Hot topics

DiME (Digi MarketEr):-TiME to SHiNE

The new sparkling DIME (Digi MarketEr) are the ones who embrace digital transformation with open arms and voraciously feed on data analytics to satisfy their performance outcomes with an informed business decision. The benefit of being DIME is that it propels data management out of the hands of individual stakeholders, and puts data sets with insights on to center glass table (Transparent workplace) for informed decision making.

Arjun Arunachalam: The Man Who Deleted Helium

For more than fifty years, the MRI industry treated...

India’s Booming OTC Pain Management Market: Trends, Growth & Consumer Behaviors

India’s Booming Pain Management Market: Trends, Growth & Consumer...

Is Pharma’s Business Model like McDonald’s? ...

Is Pharma’s business model like McDonald’s? Doing things over & over again without innovation? McDonald’s is famous for its Hamburger University, a training facility at the McDonald’s Corporation global headquarters in Chicago, Illinois. It instructs high-potential restaurant managers in restaurant management. More than 5,000 students attend Hamburger University each year and over 275,000 people have graduated with a degree in Hamburgerology. Sound familiar? Pharma’s training has been on similar lines – hire people continuously and put them through the grind of mugging up essentials of drugs for diseases that the particular company sells. While the McDonald’s model is ideal for its business of replication, it has outlived its utility in healthcare and drug companies are in danger of being reduced to mere suppliers of drugs to new digital platform businesses unless they learn to innovate.